Sign in

    Jonathan Young

    Research Analyst at Cantor Fitzgerald

    Jonathan Young is an analyst at Cantor Fitzgerald specializing in finance and international business. He has been recognized for his professional achievements in the industry, leveraging experience in financial analysis and strategic business operations. Although specific company coverage, performance statistics, and career timeline details are not provided in publicly indexed sources, his background indicates expertise in investment and global markets. Professional credentials or specific securities licenses are not listed in available records.

    Jonathan Young's questions to CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) leadership

    Jonathan Young's questions to CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) leadership • Q1 2025

    Question

    Jonathan Young asked for an update on core medical trends within the insurance business, comparing new versus existing member cohorts, and inquired about Part D out-of-pocket maximum trends. He also questioned the progress of the Counterpart Health go-to-market strategy and its potential timeline for financial contribution.

    Answer

    CFO Peter Kuipers responded that overall cost trends, for both new and returning member cohorts, are performing as expected. CEO Andrew Toy added that while the company remains excited about Counterpart Health, the immediate focus is on improving profitability in the core insurance segment, with further updates on Counterpart to be provided later in the year.

    Ask Fintool Equity Research AI

    Jonathan Young's questions to CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) leadership • Q3 2024

    Question

    Jonathan Young of Cantor Fitzgerald inquired about the early performance of the Annual Enrollment Period (AEP) for 2025, the impact of the improved STARS rating on member attraction, the nature of planned Q4 investments, and the size of the Prior Period Development (PPD) benefit.

    Answer

    CEO Andrew Toy explained that the company is well-positioned for AEP due to its new four-star rating and maintained product richness, especially as competitors retreat. CFO Peter Kuipers added that Q4 investments are focused on marketing and quality initiatives. He also clarified that while the specific PPD benefit isn't disclosed, its impact was smaller than in previous quarters.

    Ask Fintool Equity Research AI